3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Pancreatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Lymphoma, Follicular
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Recurrence
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
ibrutinib
2
Rituximab
2
venetoclax
1
ponatinib
1
fludarabine
1
enzalutamide
1
durvalumab
1
dacetuzumab
1
blinatumomab
1
Lenalidomide
1
Cyclophosphamide
1
CA-4948
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphatic Diseases
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts